2025年1月2日早间,信达生物(01801.HK)宣布将一款新药IBI3009的全球独家权益授予罗氏。 根据协议,信达生物授予罗氏IBI3009的全球开发、生产和商业化的独家权益。双方将共同负责该ADC(抗体偶联药物)候选药物的早期开发,后续临床开发将由罗氏负责。信达生物将获得8000万美金的首付款,和最高达10亿美金的开发和商业化潜在里程碑付款,以及未来基于全球年度销售净额的梯度式销售提成。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.